Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Briagen Observational Study (BOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04090970
Recruitment Status : Recruiting
First Posted : September 16, 2019
Last Update Posted : December 17, 2019
Sponsor:
Information provided by (Responsible Party):
Gemstone Biotherapeutics

Brief Summary:
This research study is evaluating a study product called Briagen™ as a possible treatment for wound healing after Mohs procedure.

Condition or disease Intervention/treatment
Mohs Surgery Device: Briagen

Detailed Description:

Briagen, the study product being used in this study, is a natural complex carbohydrate wound dressing for skin wounds created by Mohs surgery.

Briagen was developed with the intent to improve healing time and reduce scarring of skin wounds. Briagen seeks to match the mechanical aspects of your skin (thickness, stiffness, hydration, pore size) to assist in the healing process.

The purpose of this research study is to observe healing time of Briagen applied to wounds created as a result of Mohs surgery.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 30 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Briagen™ Case Study and Observation of Skin Excision Healing in Mohs and Other Dermatological Procedures
Actual Study Start Date : August 26, 2019
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : May 2020

Intervention Details:
  • Device: Briagen
    Natural complex carbohydrate wound dressing for skin wounds


Primary Outcome Measures :
  1. Healing Time [ Time Frame: 28 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patient seeking treatment for wound created by Mohs skin excision
Criteria

Inclusion Criteria:

  1. Patient seeking treatment for wound created by Mohs or other full thickness skin excisions
  2. Over 18 years of age
  3. English-speaking
  4. Presents for treatment within 24 hours of initial Mohs skin excision procedure.

Exclusion Criteria:

  1. History of significant wound complications and non-compliance on wound maintenance instructions (infections, disturbing the wound during the healing process, etc.)
  2. Known diagnosis of Diabetes
  3. Active infection in the wound bed
  4. Under 18 years of age

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04090970


Contacts
Layout table for location contacts
Contact: Emily English, PhD 443-682-7740 info@gemstonebio.com

Locations
Layout table for location information
United States, New Jersey
Dr. David Abramson Recruiting
Englewood, New Jersey, United States, 07631
Contact: David Abramson, MD    201-568-2977      
United States, North Carolina
Dermatology, Laser & Vein Specialists of the Carolinas Recruiting
Charlotte, North Carolina, United States, 28207
Contact: Razia Ludin, MHA,BSc, CCRC         
Principal Investigator: Girish Munavalli, MD         
Sponsors and Collaborators
Gemstone Biotherapeutics
Layout table for additonal information
Responsible Party: Gemstone Biotherapeutics
ClinicalTrials.gov Identifier: NCT04090970    
Other Study ID Numbers: 1001
First Posted: September 16, 2019    Key Record Dates
Last Update Posted: December 17, 2019
Last Verified: December 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: No